Thrombocytopenic purpura

Dose as per specialist.

Prescribing Notes:

Caplacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

20/04/2023

East Region Formulary content agreed.

Standard treatment for ITP (immunosuppressants and/or corticosteroids).

Dose as per specialist.

Eltrombopag is approved for restricted use by a hospital specialist for the following indications:
- In chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
- As second-line treatment for adult non-splenectomised patients where surgery is contraindicated. Use is restricted to patients with severe symptomatic ITP or a high risk of bleeding.
- Treatment of thrombocytopenia in patients with chronic hepatitis C virus infection. Where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
Romiplostim is approved for restricted use by a hospital specialist for the following indications:
- Severe symptomatic ITP or patients with a high risk of bleeding for chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
- Second line treatment for non-splenectomised patients where surgery is contra-indicated. Restricted to use in patients with severe symptomatic ITP or at high risk of bleeding.

20/04/2023

East Region Formulary content agreed.